

1 **SARS-CoV-2-specific Humoral Immune Responses after A Single dose of**  
2 **Inactivated Whole-virus SARS-CoV-2 Vaccine in Kidney Transplant**  
3 **Recipients: An Initial Report**

4 Jackrapong Bruminhent, MD<sup>1,2</sup>, Sarinya Boongird, MD<sup>2,3</sup>, Montira Assanatham, MD<sup>2,3</sup>,  
5 Sasisopin Kiertiburanakul, MD, MHS<sup>1</sup>, Kumthorn Malathum, MD<sup>1</sup>, Arkom Nongnuch, MD<sup>2,3</sup>,  
6 Angsana Phuphuakrat, MD, PhD<sup>1</sup>, Pongsathon Chaumdee, MD<sup>4</sup>, Sopon Jirasiritham, MD<sup>2,5,6</sup>,  
7 Chitimaporn Janphram, MD<sup>7</sup>, Sansanee Tossiri, MD<sup>7</sup>, Supparat Upama, MD<sup>8</sup>, Chavachol  
8 Sethaudom<sup>9,\*</sup>

9  
10 <sup>1</sup>Division of Infectious Diseases, Department of Medicine, Faculty of Medicine Ramathibodi  
11 Hospital, Mahidol University, Bangkok, Thailand

12 <sup>2</sup>Excellence Center of Organ Transplantation, Faculty of Medicine Ramathibodi Hospital,  
13 Mahidol University, Bangkok, Thailand

14 <sup>3</sup>Division of Nephrology, Department of Medicine, Faculty of Medicine Ramathibodi Hospital,  
15 Mahidol University, Bangkok, Thailand

16 <sup>4</sup>Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University,  
17 Bangkok, Thailand

18 <sup>5</sup>Division of Vascular and Transplant Surgery, Department of Surgery, Faculty of Medicine  
19 Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.

20 <sup>6</sup>Praram 9 Hospital, Bangkok, Thailand

21 <sup>7</sup>Somdech Phra Debaratana Medical Center, Faculty of Medicine Ramathibodi Hospital, Mahidol  
22 University, Bangkok, Thailand

23 <sup>8</sup>Samitivej Hospital Sukhumvit, Bangkok, Thailand

24 <sup>9</sup>Immunology Laboratory, Department of Pathology, Faculty of Medicine Ramathibodi Hospital,  
25 Mahidol University, Bangkok, Thailand

26

27 **\*Correspondence**

28 Chavachol Sethaudom

29 [chavachol@hotmail.com](mailto:chavachol@hotmail.com)

30 **Abstract**

31 We presented an initial pilot study report focused on immunogenicity and safety  
32 following an inactivated whole-virus severe acute respiratory syndrome coronavirus 2  
33 vaccination among kidney transplant (KT) recipients. At four weeks after the first dose of  
34 vaccine, the level of anti-receptor-binding domain IgG antibody was not significantly different  
35 compared to before vaccination in 30 KT recipients ( $p = 0.45$ ). Moreover, a significant lower  
36 mean (95% CI) anti-receptor-binding domain IgG antibody was observed compared to 30  
37 immunocompetent controls (2.4 [95% CI 1.3-3.5] vs. 173.1 [95% CI 88.3-2,457.9] AU/mL,  $p <$   
38  $0.001$ ). Mild adverse events included fever (17%) and localized pain at the injection site (14%)  
39 were observed after vaccination.

40 **Brief report**

41 Solid-organ transplant (SOT) recipients are at greater risk of significant coronavirus  
42 disease 2019 (COVID-19) related morbidity and mortality.<sup>1</sup> Immunization against severe acute  
43 respiratory syndrome coronavirus 2 (SARS-CoV-2) is considered one of the most promising  
44 strategies to alleviate unfavorable consequences among SOT recipients and their allograft.

45 Several platforms of the SARS-CoV-2 vaccine were developed and utilized variably  
46 worldwide among immunocompetent individuals. Data on SARS-CoV-2-specific immune

47 responses among patients with immunocompromised states such as those receiving SOT has  
48 been scarce. Few recent studies evaluated the immunogenicity of SARS-CoV-2 messenger RNA  
49 vaccine in SOT recipients receiving immunosuppressant revealed an acceptable safety profile.  
50 However, a significant proportion of recipients who developed suboptimal immunologic  
51 response after a single and double dose of the vaccine is a concern (17% and 54%,  
52 respectively).<sup>2,3,4</sup> On the other hand, immunogenicity, and safety following immunization with an  
53 inactivated whole-virus SARS-CoV-2 vaccine among SOT recipients have not been assessed.<sup>5</sup>

54 A pilot, multi-center, prospective study of adult Asian KT recipients who received a 4-  
55 week interval immunization of an inactivated whole-virus SARS-CoV-2 vaccine, CoronaVac<sup>®</sup>  
56 (Sinovac Biotech Ltd.) was conducted from April 2021 to June 2021. SARS-CoV-2-specific  
57 humoral immunity was measured before, one month after the first dose, using a quantitative  
58 assay of SARS-CoV-2 immunoglobulin G (IgG) assay (Abbott diagnostics) that tests for  
59 antibodies against the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein, which  
60 reported in arbitrary units (AU)/mL. Those were also referenced to immunocompetent patients.  
61 The study was approved by the Institutional Review Board of the Faculty of Medicine  
62 Ramathibodi Hospital, Mahidol University, Bangkok, Thailand (MURA2021/242). All patients  
63 provided written informed consent prior to participation.

64 A total of adult 60 patients was recruited into the study and comprised of  
65 immunocompetent patients (n=30) and KT recipients (n=30). Among KT recipients, the median  
66 age was 47 years (interquartile range [IQR], 41-52 years), and 67% of them were men. The  
67 median time since transplant was 3.6 years (IQR, 2-9.5 years). The maintenance  
68 immunosuppression regimen included tacrolimus (57%), cyclosporine (29%), corticosteroids  
69 (97%), mycophenolic acid (91%), sirolimus (3%), and everolimus (3%). At four weeks after the

70 first dose of vaccine, a mean (95% confidence interval [CI]) of anti-receptor-binding domain  
71 IgG antibody was not significantly different compared to before vaccination in all participants ( $p$   
72 = 0.45) **Figure 1.** KT recipients developed significantly lower anti-receptor-binding domain IgG  
73 antibody compared to immunocompetent patients (2.4 [95% CI 1.3-3.5] vs. 173.1 [95% CI 88.3-  
74 2,457.9] AU/mL,  $p < 0.001$ ). Approximately half of the participants did not report any adverse  
75 events (AEs) followed by mild AEs such as fever (17%) and pain at the injection site (14%). No  
76 serious AEs observed.

77 Our initial report revealed that KT recipients receiving the first dose of an inactivated  
78 whole-virus SARS-CoV-2 vaccine could remain vulnerable to infection, however, with  
79 infrequent and mild adverse reactions. A complete result is ongoing, and further large-scale  
80 studies reaffirmed this result is needed (Thai Clinical Trials Registry, TCTR20210226002).

81

## 82 **Disclosure**

83 The authors of this manuscript have no conflicts of interest to disclose

84

## 85 **Funding**

86 This study was granted by the National Research Council of Thailand (102912).

87

## 88 **References**

89

- 90 1. Hadi YB, Naqvi SF, Kupec JT, Sofka S, Sarwari A. Outcomes of Coronavirus Infectious  
91 Disease -19 (COVID-19) in Solid Organ Transplant Recipients: A Propensity Matched  
92 Analysis of a Large Research Network. *Transplantation*. 2021 Feb 5.

- 93 2. Marion O, Del Bello A, Abravanel F, Couat C, Faguer S, Esposito L, Hebral AL, Izopet  
94 J, Kamar N. Safety and Immunogenicity of Anti-SARS-CoV-2 Messenger RNA  
95 Vaccines in Recipients of Solid Organ Transplants. *Ann Intern Med.* 2021 May 25.
- 96 3. Boyarsky BJ, Werbel WA, Avery RK, Tobian AAR, Massie AB, Segev DL, Garonzik-  
97 Wang JM. Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine  
98 in Solid Organ Transplant Recipients. *JAMA.* 2021 May 4;325(17):1784-1786.
- 99 4. Boyarsky BJ, Werbel WA, Avery RK, Tobian AAR, Massie AB, Segev DL, Garonzik-  
100 Wang JM. Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid  
101 Organ Transplant Recipients. *JAMA.* 2021 May 5:e217489.
- 102 5. Baraniuk C. What do we know about China's covid-19 vaccines? *BMJ.* 2021 Apr  
103 9;373:n912.

104

105 **Figure legend**

106 **Figure 1 A** mean with 95% confidence interval of anti-receptor-binding domain  
107 immunoglobulin G antibody in immunocompetent patients and kidney transplant recipients  
108 before and at four weeks after a single dose of inactivated whole-virus SARS-CoV-2 vaccine.

109

110

